DS
Therapeutic Areas
Scancell Pipeline
| Drug | Indication | Phase |
|---|---|---|
| iSCIB1+ (SCIB1) | Advanced Unresectable Melanoma | Phase 2/3 |
| Modi-1 | Advanced Solid Tumors (including Renal Cell Carcinoma) | Phase 1/2 |
Leadership Team at Scancell
PL
Phil L'Huillier
Chief Executive Officer
PL
Professor Lindy Durrant
Chief Scientific Officer
SN
Sath Nirmalananthan
Chief Financial Officer & Company Secretary
DN
Dr Nermeen Varawalla
Chief Medical Officer
DM
Dr Mandeep Sehmi
Head of Business Development
DC
Dr Callum Scott
Senior Vice President of Development
DS
Dr Shamim Kazmi-Stokes
Head of Programme Management
PA
Philip Angell-Manning
Head of CMC
AH
Alex Hayward
Head of Finance